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Abstract 
Background: Treatment with second‑generation antihistamines is recommended in patients with chronic spontane‑
ous urticaria (CSU). Some patients remain unresponsive even after up‑dosing up to fourfold. Many third line treatment 
options have limited availability and/or give rise to significant side effects. We investigated effectiveness and safety of 
antihistamine treatment with dosages up to fourfold and higher.
Methods: This retrospective analysis of patients’ records was performed in adult CSU patients suffering wheals 
and/or angioedema (AE). Demographic, clinical, and therapeutic data was extracted from their medical records. We 
recorded the type, maximum prescribed dosage, effectiveness, and reported side effects of antihistamine treatment.
Results: Of 200 screened patients, 178 were included. Treatment was commenced with a once daily dose of anti‑
histamines. Persisting symptoms meant that up‑dosing up to fourfold occurred in 138 (78%) of patients, yielding suf‑
ficient response in 41 (23%). Up‑dosing antihistamines was necessary in 110 (80%) patient with weals alone or weals 
with angioedema and 28 (64%) with AE only (p = 0.039). Of the remaining 97 patients with insufficient response, 
59 were treated with dosages higher than fourfold (median dosage 8, range 5–12). This was sufficient in 29 patients 
(49%). Side effects were reported in 36 patients (20%), whereof 30 (17%) experienced somnolence. Side effects after 
up‑dosing higher than fourfold were reported in six out of 59 patients (10%).
Conclusion: Up‑dosing antihistamines higher than fourfold dosage seems a feasible therapeutic option with regards 
to effectiveness and safety. The need for third line therapies could be decreased by 49%, with a very limited increase 
of reported side effects.
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Background
Chronic urticaria is either inducible (CINDU) or sponta-
neous (CSU) or both [1, 2]. Angioedema (AE) can occur 
concurrently with urticaria in up to 40% of cases, and 
may occur alone in up to 10–20% of cases [3]. Patients 
suffering CSU can have wheals only, AE only, or both [1].
The therapeutic approach of chronic urticaria aims at 
symptom relief. Licensed doses (1 tablet daily) of modern 
second-generation antihistamines (sgAH) are the first 
line treatment. An increase in the dose only up to four-
fold is recommended as second line treatment [1, 4]. 
However, every third to fourth patient will remain symp-
tomatic despite up-dosing up to fourfold [5], hence alter-
native treatments are needed for (partially) unresponsive 
patients [1]. Current third-line—in the US guideline 
fourth-line—treatment options consist of omalizumab, 
cyclosporine A (CsA) or leukotriene receptor antagonist 
montelukast [1, 4]. However, each of these options has 
limitations: omalizumab is expensive and not reimbursed 
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For leukotriene receptor antagonists, the level of evi-
dence for efficacy is low [1].
In our tertiary center, refractory patients were treated 
with antihistamines at varying dosages (including dos-
ages higher than fourfold), in order to avoid the use of 
CsA as omalizumab had not yet been approved for treat-
ment of CSU. Despite a lack of controlled studies, experts 
have reported benefit of dosing antihistamines higher 
than fourfold in CSU patients [6]. The objective of this 
study was to investigate the frequency of ineffective-
ness of treatment with antihistamines up to fourfold the 
standard dose in patients with CSU, and to determine the 
effectiveness and safety of antihistamine treatment above 
fourfold the standard dose,.
Methods
Study design and subjects
A retrospective analysis of patients’ records was per-
formed in patients visiting our tertiary dermatology and 
allergology clinic for the evaluation of chronic urticaria 
and/or angioedema in 2012 (before registration of omali-
zumab), and for each patient all available data were col-
lected up to 2014. Adult patients suffering CSU (wheals 
and/or AE for at least 6 weeks) were selected. All patients 
with other diagnoses including acute urticaria (dura-
tion of symptoms less than 6  weeks), CINDU including 
symptomatic dermographism, urticaria or angioedema 
caused by allergy or of other known causes, urticaria pig-
mentosa and urticaria vasculitis were excluded. Medical 
records were screened to verify inclusion and exclusion 
criteria. To be recognized as a representative sample, 159 
patients were needed (based on a margin of error of 5%, 
a confidence interval of 95% and an eligible population 
of 268 patients) [7]. To have a representation of both AE 
patients and patients with wheals, all 100 available AE 
patients and 100 additional patients with wheals were 
screened for inclusion in the study. Patients with wheals 
were randomly selected based on their unique patient 
identification number in the electronic medical record 
system; dossiers of the patients with the lowest num-
bers were screened until 100 patients with wheals were 
included.
Data were collected as described below, and used in 
strictly anonymous form, according to the code of con-
duct for medical research approved by the hospital’s 
Medical Ethical Committee. Written informed consent 
for the publication of this report was not required from 
the patients, as approved by the Ethics Committee, pro-
tocol number 13-459.
Treatment regimen
The local treatment protocol, as shown in Fig.  1, com-
menced with the approved dosage of antihistamine, and 
in case of persisting symptoms up-dosing occurred up to 
fourfold. Higher than fourfold dosages were only used in 
patients who remained symptomatic at fourfold antihis-
tamine dosages. Treatment adjustments were performed 
individually by all prescribing physicians of the depart-
ment. Patients often were already on antihistamine treat-
ment prior to their first visit at the clinic. In this case, 
they did not have to start at the licensed dosage, but 
could further follow the local protocol. All treatment was 
open. At the start of the study, standard disease-specific 
questionnaires were not yet available and therefore not 
used.
Data collection
After inclusion, data was collected from electronic 
patient records. Data regarding demographic and thera-
peutic characteristics until 2014 was extracted manually 
from the electronic medical records from each patient’s 
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- cetirizine 10 mg
- desloratadine 5 mg
- ebastine 10 mg
- fexofenadine 120 mg
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- hydroxyzine 10 mg 
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Fig. 1 Local treatment protocol. When patients were already on antihistamine treatment prior to their first visit at the clinic, they could further fol‑
low the local protocol. Evaluation was planned every 3–6 months, or earlier if symptoms are intolerable
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of antihistamines patients were treated with, the maximal 
prescribed dosage, treatment results, and reported side 
effects.
For each patient antihistamine use was recorded as 
daily treatment as well as rescue medication., The type, 
maximal prescribed dosage, treatment results including 
clinical symptoms of wheals, angioedema, and itch, and 
reported side effects were also recorded. Antihistamines 
were prescribed prior to or during consultations at this 
tertiary hospital. In the Netherlands, all types and dos-
ages of antihistamines are reimbursed, hence prescribing 
is not affected by insurance. The doctor’s reported effect 
from each treatment option was allocated by the inves-
tigators into one of two categories: sufficient or insuffi-
cient. Disagreements were discussed and resolved. When 
the dose of antihistamines was raised and further infor-
mation was missing, it was interpreted that lower doses 
did not reach sufficient response. The reported effect 
from dosages higher than fourfold was further subdi-
vided into four different categories: (1) no effect (2) insuf-
ficient effect and patient not satisfied, (3) partial disease 
control, and patient satisfied, or (4) completely free of 
symptoms. If information was unclear category alloca-
tion was performed by two investigators. Up-dosing 
higher than fourfold was preferably performed by com-
bining more than one type of antihistamine. In these 
cases the effect of one specific antihistamine was unclear 
and was not included for analysis. In case of side effects, 
the type of side effect as reported in the medical record, 
as well as the corresponding eliciting dosage of antihis-
tamines, were recorded. Additional blood tests were not 
performed routinely.
Analyses
Descriptive statistics were performed using IBM SPSS 
Statistics version 21. To explore differences in the pro-
portion of patients with sufficient or insufficient effect 
from antihistamines in the three subgroups of patients 
(wheals only, AE only, and both wheals and AE), patients 
with unknown effect of treatment were excluded, and 
the Pearson Chi Square (Chi square) test was used. The 
Fisher-Freeman-Halton exact (Fischer’s exact) test was 
used in cases of low numbers.
Results
Population
Of the 200 screened patients, 178 patients (121 [68%] 
female; median age 48.2 years [range 20–87]) were diag-
nosed with CSU and were included in the study, includ-
ing 10 patients who suffered both CSU and CINDU. Five 
of 200 were excluded due to angioedema with known 
causes (1 with HAE, 1 with specific allergy, and 3 with 
ACEi-AE) and 17 were excluded since they had only 
inducible symptoms (CINDU). Of the included 178, 43 
patients (24%) had wheals only, 44 (25%) had AE only, 
and the remaining 91 (51%) suffered both symptoms. 
The median disease duration before the first consulta-
tion at our University referral center was 1  year (range 
0–41.5  years). Ninety-four patients (53%) reported that 
they had previously visited another dermatologist or 
allergologist for evaluation of wheals and/or AE. All visits 
per patient were reviewed, and this comprised a median 
number of visits of 2 (range 1–57) and an additional 
median number of 2 consultations per telephone (range 
0–24).
Maximum doses and effectiveness of antihistamines
All 178 included patients were initially treated with the 
licensed, once daily, dosage of antihistamines (Fig.  2). 
Of them, 27 patients (15%) used antihistamines only on 
demand. In 138 patients (78%) the licensed dose was inef-
fective and in all these refractory patients the dose was 
raised up to fourfold. This remained ineffective in 97 
(70%). Subsequently, 59 of these 97 patients were treated 
with higher doses of antihistamines by combining two 
types of second generation antihistamines with a maxi-
mum of eightfold the licensed dose. The median maximal 
combined dose of antihistamines in these 59 was eight-
fold (range 5–8), however in 8 individuals the dose was 
raised further (range 9–12). Ten of 59 patients (17%) 
subsequently became completely free of symptoms, and 
nineteen patients (32%) had sufficient results. Thus, in 
49% of patients a higher than fourfold dose reduced or 
completely eliminated symptoms. The remaining 38 of 
the 97 refractory patients received no further treatment 
(n = 28), or further treatment was unknown (n = 8), or 
they received other types of therapy including ultravio-
let (UV) treatment (n = 2), for which effectiveness results 
were not included in the current study (Fig. 2).
Need for up‑dosing in wheals versus AE without wheals
Up-dosing up to fourfold was necessary more frequently 
in patients with wheals (wheals only: 35 of 43 patients; 
81%, wheals and AE: 75 of 91 patients; 82%) than in AE 
without wheals (28 of 44 patients; 64%; p = 0.039). How-
ever, when looking specifically at those with only one of 
the two symptoms, there was no statistically significant 
difference between wheals only and AE only (p = 0.053, 
Table 1a). 
A trend was observed that up-dosing higher than 
fourfold was also necessary more often in patients with 
wheals (17; 40%) compared to AE only (7; 16%; p = 0.056, 
Table 1a).
Response to antihistamine dosages higher than four-
fold dichotomized as sufficient (29 patients [58%]) versus 
insufficient (21 patients [42%]) did not differ between the 
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three diagnosis groups (p = 0.530, Table 1b), or between 
patients with wheals only or AE only (p = 0.620).
Types of antihistamines
The 178 patients received a total of 354 antihistamine 
prescriptions. As shown in Table 2, the most frequently 
prescribed antihistamines were levocetirizine (71% of 
patients), desloratadine (56%) and fexofenadine (23%). A 
total of 35 patients (20%) were treated with clemastine, 
and 26 patients (15%) were treated with hydroxyzine. 
Since 12 patients were treated with both hydroxyzine and 
clemastine at any time during their disease, a total of 49 
patients (28%) received first-generation antihistamines 
(fgAH). All patients who were treated with fgAH were 
refractory to licensed doses: 13 (27%) received fgAH as 
part of up-dosing up to fourfold, and the remaining 36 
(73%) received fgAH in addition to sgAH to reach total 
dosages of antihistamines higher than fourfold. Clem-
astine was up-dosed in 11 patients up to 3 mg per 24 h 
period, and hydroxyzine in nine patients up to 75 mg per 
24 h.
Safety of antihistamines
Of the 178 patients 36 (20%) reported side effects upon 
treatment with antihistamines independent of the dos-
age. Fifteen of 36 patients reported side effects for 
two (n  =  14) or three (n  =  1) different antihistamines 
(Table  3). Somnolence (Fig.  3a) was reported in 30 of 
36 patients (83%), including 5 patients (10%) treated 
with fgAH and 28 (16%) with sgAH. Six out of 36 (17%) 
reported side effects only during treatment with dosages 
higher than fourfold (Fig. 3b). They consisted of somno-
lence in five patients and were unclear in 1. Vomiting or 
diarrhea were not reported by any of the patients.
Discussion
In CSU patients refractory to up to fourfold doses of 
antihistamines, higher than fourfold dosages reduced or 
completely eliminated symptoms in an additional 49%. 
Side effects were reported in 20% of patients and con-
sisted mainly of somnolence. After up-dosing higher than 
fourfold only 6 out of 59 patients (10%) reported side 
effects.
In more than half of the total population response 
remained insufficient despite antihistamine treatment 
up to fourfold, consistent with previous studies [8–10]. 
Up-dosing higher than fourfold, with a median dose of 
eight tablets daily, was effective in half of patients includ-
ing those with wheals only, with AE only, and with both 
symptoms. This is promising, since antihistamines have 
low costs as opposed to CsA or omalizumab, and they are 
available worldwide [1]. There is a lack of rationale for the 
dosage of fourfold being the maximum. In contrast, in 
both CSU and in cold urticaria, treatment with four tab-
lets per day was shown to be more effective than three 
tablets per day, which in turn was more beneficial than 
two tablets or one tablet per day, indicating that higher 
doses could be more effective [9, 11]. Moreover, hydrox-
yzine is prescribed up to 200 mg/day, and because 30 mg 
of hydroxyzine equals about 10 mg cetirizine [11]. Two-
hundred mg equals a dose of 60 mg cetirizine/day, con-
siderably higher than fourfold. Since such high dosages 
of hydroxyzine are used in daily practice, it was likely 
that higher dosages of other antihistamines could also be 
effective. Additionally, hydroxyzine is a first generation 
antihistamine with considerably more side-effects than 
cetirizine. We conclude that many patients indeed had 
a favorable response to higher doses of antihistamines 







Up to fourfold dose:
138
Higher than fourfold dose:
59
No effect: 1 (2%)
Insufficient: 20 (34%)
Sufficient: 19 (32%)
No symptoms: 10 (17%)
Unknown: n=9
Need for additional treatment: 97
(54% of population)
Need for additional
treatment reduced by 49%





Fig. 2 Antihistamine dosages and results. The following dosages 
were considered as standard dose: levocetirizine 5 mg, desloratadine 
5 mg, fexofenadine 180 mg, clemastine 1 mg, hydroxyzine 25 mg, 
cetirizine 10 mg, loratadine 10 mg, acrivastine 8 mg three times daily
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The effect of antihistamines, but only up to fourfold, 
has been studied previously, but very few head-to-head 
studies have been performed [9, 12]. Some studies have 
examined antihistamines up to fourfold [9, 13], or four 
tablets daily [8]. The latter may be somewhat confusing, 
for instance for fexofenadine where both 120 and 180 mg 
tablets are available. There are also studies available where 
only twofold dosages were the maximum [10]. Some stud-
ies showed preponderance of efficacy of higher dosages in 
the treatment of chronic spontaneous urticaria [8–10, 14], 
and cold and cholinergic urticaria [15–18]. In contrast, in 
some other studies comparable efficacy of standard and 
higher dosages was found [19–22].
The most frequently used antihistamine were sgAH. 
The use of fgAH is discouraged in the European guide-
line [1] since serious side-effects of these old sedating 
antihistamines have been reported, including lethal over-
doses. Additionally, in the elderly they increase the risk 
of impaired cognition, inattention, disorganized speech, 
altered consciousness, and falls [1]. Yet, a substantial 
number of patients was treated with fgAH at some time 
during their disease: clemastine was prescribed to 20% 
Table 1 Frequencies of up-dosing (a) and effectiveness of antihistamine dosages higher than fourfold (b)
* One patient suffering wheals only reported no effect of up-dosing to fivefold or higher, this case is included in the group of patients with insufficient effect. There 
was no statistically significant difference in treatment result between the three groups (Fischer’s exact p = 0.530) nor in those with wheals only (included for analysis: 
n = 17) and AE only (n = 7, Fischer’s exact p = 0.620)
a Percentages are shown per row to enable comparison between diagnoses groups. Patients are shown in their maximum dosage group, thus patients who received 
fivefold or higher have previously been treated with lower doses. Numbers therefore differ from Fig. 1. There was no statistically significant difference in frequency 
of up-dosing between the three groups (Chi square p = 0.053), and also not between those with wheals only (included for analysis: n = 35) and AE only (n = 28; Chi 
square p = 0.056). n.a. not applicable
b Percentages are shown per row to enable comparison between diagnoses groups. Effect of treatment was unknown in nine patients, the numbers of patients 
therefore differ from Table 1a








AE only 16 (36) 21 (48) 7 (16) 44 (100%)
Wheals only 8 (19) 18 (42) 17 (40) 43 (100%)
AE and wheals 16 (18) 40 (44) 35 (38) 91 (100%)








AE only 2 (33) 2 (33) 2 (33) 6 (100%)
Wheals only 7 (58) 3 (25) 2 (17) 12 (100%)
AE and wheals 12 (38) 14 (44) 6 (19) 32 (100%)
Table 2 Frequency of use and frequency of satisfying result per antihistamine
Frequency data are presented as numbers and percentages of the total population (n = 178), and frequencies of sufficient response are presented as percentages of 
those treated with the specific antihistamine
* In 1 patient it was unknown which dose caused sufficient effect. n.a. not applicable. Please note that in most patients where up-dosing higher than fourfold 












Levocetirizine 5 mg 126 (71) 15 (12) 26 (21) 2 (0–6)
Desloratadine 5 mg* 99 (56) 1 (1) 15 (15) 4 (1–6)
Fexofenadine 180 mg 41 (23) 5 (12) 2 (5) 1 (0–2)
Clemastine 1 mg 35 (20) 1 (3) 2 (6) 2 (1–2)
Hydroxyzine 25 mg 26 (15) 0 (0) 1 (4) 3 (n.a.)
Cetirizine 10 mg* 16 (9) 2 (13) 2 (13) 1.5 (1–4)
Loratadine 10 mg 9 (5) 0 (0) 1 (11) 2 (n.a.)
Acrivastine 3 × 8 mg 2 (1) 0 (0) 0 (0) n.a.
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and hydroxyzine to 15%. It was previously suggested that 
some physicians were not fully aware of the content of 
the most recent guidelines and therefore did not follow 
them [23]. However, the successful use of fgAH after fail-
ure of treatment with sgAH has been described [24]. Fur-
thermore, the US guideline does support the use of fgAH 
in patients who do not achieve control of their condition 
with higher-dose second-generation antihistamines [4]. 
Our results support that the addition of not only sgAH 
but also of fgAH can lead to sufficient disease control 
when either licensed doses of sgAH, or dosages up to 
fourfold had failed.
Somnolence was reported by a minority of patients. 
It is well known that somnolence is one of the most 
reported unwanted effects of antihistamines. It occurs 
even when using sgAH [9] in up to 23% of patients [8], 
and it does not significantly increase when comparing 
with baseline somnolence [9], or when antihistamine 
doses are increased [8]. This was confirmed in our study 
for even higher dosages. Patients treated with fgAH did 
not report sedation more often than those treated with 
only sgAH. A possible explanation for this is that fgAH 
were mostly used in low dosages in addition to high dos-
ages of sgAH, whereas often times relatively high doses 
of fgAH are used [24–26]. Very few of the side effects 
(10%) were reported only when antihistamine dosages 
were raised higher than fourfold. For desloratadine it 
was previously shown that dosages up to ninefold did not 
lead to clinically relevant adverse effects [27]. The low 
frequency of somnolence in the current study is likely to 
be an underestimation of unwanted effects due to miss-
ing information or recall bias, and since patients were 
not all actively asked about side effects, including but not 
limited to somnolence. It could also be caused by toler-
ance to somnolence which can develop within 4  days 
of subsequent use of H1 antihistamines [24, 28]. It was 
hypothesized that this is caused by adapted neurophar-
macological effects [28]. On the other hand, it remains 
difficult to distinguish somnolence caused by treatment 
Table 3 Frequency of side effects per antihistamine
Data are presented as numbers and percentages of patients treated with this antihistamine. Patients may have reported side effects upon treatment with more than 
one antihistamine, therefore the numbers do not match the total number of patients reporting at least one side effect. “Other” side effects occurred in one patient 
each, unless otherwise specified. Percentages are rounded and may therefore not match within one row. Please note that a low frequency of side effects may be due 








Levocetirizine 5 mg 28 (22) 22 (17) 6 (5) Weight gain (n = 2), palpitations, increase of symptoms, unclear (n = 2)
Desloratadine 5 mg 14 (14) 9 (9) 5 (5) Palpitations, headache, increase of symptoms (n = 2), unclear (n = 2)
Fexofenadine 180 mg 2 (5) 1 (2) 1 (2) Increase of symptoms
Clemastine 1 mg 3 (9) 2 (6) 1 (3) Increased intra‑ocular pressure
Hydroxyzine 25 mg 3 (12) 3 (12) 0 (0) n.a.
Cetirizine 10 mg 0 (0) 0 (0) 0 (0) n.a.
Loratadine 10 mg 1 (11) 1 (11) 0 (0) n.a.







































Fig. 3 Frequency of side effects, by a type of side effect, and  
b maximum dose. The following dosages were considered as 
standard dose: levocetirizine 5 mg, desloratadine 5 mg, fexofenadine 
180 mg, clemastine 1 mg, hydroxyzine 25 mg, cetirizine 10 mg, lorata‑
dine 10 mg, acrivastine 8 mg three times daily
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from somnolence caused by sleep disturbances due to 
the disease [8, 9]. Pruritus is most bothersome during 
the evening and at night when it makes falling asleep dif-
ficult and wakes patients later in the night. This causes 
chronic fatigue with a direct impact on QoL and physical 
and emotional well-being [5]. Still, although the influence 
of prolonged treatment on somnolence may be limited, 
and improvement of urticarial symptoms reduces som-
nolence [9], urticaria patients report sleep difficulties 
almost twice as often as control subjects [29], and our 
results support that somnolence occurred in a minority 
of urticaria patients [8].
A limitation of this study is the retrospective design. 
Therefore, precise documentation of results of treatment 
was missing in some patients. Also, there was a lack of 
objective measurements of effectiveness. With regard 
to side effects, we presented these as collected from the 
medical records. Somnolence was the most frequently 
named side effect. Liver and kidney function tests were 
not performed routinely. However, the extent of miss-
ing information was rather limited and different results 
are therefore not expected. Furthermore, the EAACI/
GA2LEN/EDF/WAO urticaria guideline does not recom-
mend to combine antihistamines [1], since the mecha-
nism of action of sgAH is similar and mixing different 
antihistamines would therefore theoretically not have 
additional benefits [12]. In the current study we com-
bined different antihistamines. This was performed in 
case dosages higher than fourfold were given, to limit 
side-effects related to a specific antihistamine. Lastly, 
CSU is a self-limiting disease. In the current study spon-
taneous remission may have occurred and this would 
then be misinterpreted as effectiveness of treatment.
In conclusion, we show that by up-dosing antihista-
mines higher than fourfold, half of patients reached suffi-
cient treatment response while causing a limited increase 
in side effects. The need for other third line therapies 
could be decreased considerably. These findings need 
to be confirmed in a prospective controlled study. The 
results are of special interest in case of side effects or 
contraindications to currently proposed third line treat-
ments, or when they are locally not (yet) available.
Abbreviations
AE: angioedema; CINDU: chronic inducible urticaria; CsA: cyclosporine A; CSU: 
chronic spontaneous urticaria; fgAH: first generation antihistamines; IH‑AAE: 
idiopathic histaminergic acquired angioedema; InH‑AAE: idiopathic nonhista‑
minergic acquired angioedema; sgAH: second generation antihistamines.
Authors’ contributions
IB, KH, OK, AL, ME, and HO participated in database design, data extraction, 
and performed the statistical analysis. AL, HR, CB, ME, and AK participated in 
medical dossier completion. ME, HO, and AK participated in the study design 
and ethics committee procedures. The manuscript was drafted by IB, KH, OK, 
AL, ME, HO, HR, and AK, All authors read and approved the final manuscript.
Acknowledgements
We thank Andrew Walker for proofreading the manuscript. We thank Novartis 
Pharma NL for providing an unrestricted grant to support this study.
Competing interests
MT. van den Elzen has received speakers fees from Novartis. A.C. Knulst is 
member of the national and international Novartis omalizumab advisory 
council, and has received speakers fees from Novartis and sponsoring for 
scientific studies from Novartis and Pharming. All other authors declare that 
they have no competing interests.
Availability of data and materials
Please contact author for data requests.
Ethics approval and consent to participate
The study was performed according to the code of conduct for medical 
research approved by the University Medial Center Utrecht Medical Ethical 
Committee (METC). Written informed consent for the publication of this report 
was not required from the patients, as approved by the Ethics Committee, 
protocol number 13‑459.
Funding
The database used for this study was funded by an unrestricted grant from 
Novartis Pharma NL.
Received: 7 November 2016   Accepted: 3 February 2017
References
 1. Zuberbier T, Aberer W, Asero R, Bindslev‑Jensen C, Brzoza Z, Canonica GW, 
et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, clas‑
sification, diagnosis, and management of urticaria: the 2013 revision and 
update. Allergy. 2014;69:868–87. doi:10.1111/all.12313.
 2. Weller K, Zuberbier T, Maurer M. Chronic urticaria: tools to aid the diagno‑
sis and assessment of disease status in daily practice. J Eur Acad Dermatol 
Venereol. 2015;29:38–44. doi:10.1111/jdv.13200.
 3. Fine LM, Bernstein JA. Urticaria guidelines: consensus and controversies 
in the European and American guidelines. Curr Allergy Asthma Rep. 
2015;15:30. doi:10.1007/s11882‑015‑0535‑z.
 4. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. 
The diagnosis and management of acute and chronic urticaria: 2014 
update. J Allergy Clin Immunol. 2014;2014(133):1270–7. doi:10.1016/j.
jaci.2014.02.036.
 5. Maurer M, Weller K, Bindslev‑Jensen C, Giménez‑Arnau A, Bousquet 
PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous 
urticaria. A GA2LEN task force report. Allergy Eur J Allergy Clin Immunol. 
2011;66:317–30.
 6. Wieder S, Maurer M, Lebwohl M. Treatment of severely recalcitrant 
chronic spontaneous urticaria: a discussion of relevant issues. Am J Clin 
Dermatol. 2015;16:19–26. doi:10.1007/s40257‑014‑0103‑7.
 7. Raosoft sample size calculator. http://www.raosoft.com/samplesize.html. 
Accessed 6 July 2016.
 8. Weller K, Ziege C, Staubach P, Brockow K, Siebenhaar F, Krause K, et al. 
H 1‑antihistamine up‑dosing in chronic spontaneous urticaria: patients’ 
perspective of effectiveness and side effects—a retrospective survey 
study. PLoS ONE. 2011;6:1–6.
 9. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, 
et al. The effectiveness of levocetirizine and desloratadine in up to 4 
times conventional doses in difficult‑to‑treat urticaria. J Allergy Clin 
Immunol. 2010;125:676–82. doi:10.1016/j.jaci.2009.11.047.
 10. Giménez‑Arnau A, Izquierdo I, Maurer M. The use of a responder analysis 
to identify clinically meaningful differences in chronic urticaria patients 
following placebo‑controlled treatment with rupatadine 10 and 20 mg. J 
Eur Acad Dermatol Venereol. 2009;23:1088–91.
 11. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma 
Immunol Res. 2012;4:326–31.
Page 8 of 8van den Elzen et al. Clin Transl Allergy  (2017) 7:4 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 12. Church MK. Does antihistamine up‑dosing solve chronic spontane‑
ous urticaria? Curr Treat Options Allergy. 2016;3:416–22. doi:10.1007/
s40521‑016‑0098‑9.
 13. Godse K. Ebastine in chronic spontaneous urticaria in higher doses. 
Indian J Dermatol. 2011;56:597. doi:10.4103/0019‑5154.87168.
 14. Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina I, Fantin S, et al. 
Once‑daily rupatadine improves the symptoms of chronic idiopathic 
urticaria: a randomised, double‑blind, placebo‑controlled study. Eur J 
Dermatol. 2007;17:223–8. doi:10.1684/ejd.2007.0153.
 15. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up‑dosing with 
bilastine results in improved effectiveness in cold contact urticaria. 
Allergy. 2013;68:921–8. doi:10.1111/all.12171.
 16. Metz M, Scholz E, Ferrán M, Izquierdo I, Giménez‑Arnau A, Maurer M. 
Rupatadine and its effects on symptom control, stimulation time, and 
temperature thresholds in patients with acquired cold urticaria. Ann 
Allergy Asthma Immunol. 2010;104:86–92. doi:10.1016/j.anai.2009.11.013.
 17. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High‑dose 
desloratadine decreases wheal volume and improves cold provoca‑
tion thresholds compared with standard‑dose treatment in patients 
with acquired cold urticaria: a randomized, placebo‑controlled, 
crossover study. J Allergy Clin Immunol. 2009;123:672–9. doi:10.1016/j.
jaci.2008.12.008.
 18. Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of 
cetirizine in cholinergic urticaria. Acta Derm Venereol. 1995;75:147–9.
 19. Gimenez‑Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G, 
et al. Rupatadine in the treatment of chronic idiopathic urticaria: a 
double‑blind, randomized, placebo‑controlled multicentre study. Allergy. 
2007;62:539–46. doi:10.1111/j.1398‑9995.2007.01330.x.
 20. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for 
treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 
2000;84:517–22. doi:10.1016/S1081‑1206(10)62515‑X.
 21. Finn AF, Kaplan AP, Fretwell R, Qu R, Long J. A double‑blind, placebo‑
controlled trial of fexofenadine HCl in the treatment of chronic idiopathic 
urticaria. J Allergy Clin Immunol. 1999;104:1071–8.
 22. Paul E, et al. Fexofenadine hydrochloride in the treatment of chronic 
idiopathic urticaria: a placebo‑controlled, parallel‑group, dose‑ranging 
study. J Dermatol Treat. 1998;9(3):143–9.
 23. Weller K, Viehmann K, Bräutigam M, Krause K, Siebenhaar F, Zuberbier 
T, et al. Management of chronic spontaneous urticaria in real life—in 
accordance with the guidelines? A cross‑sectional physician‑based 
survey study. J Eur Acad Dermatol Venereol. 2013;27:43–50.
 24. Kaplan AP. What the first 10,000 patients with chronic urticaria have 
taught me: a personal journey. J Allergy Clin Immunol. 2009;123:713–7. 
doi:10.1016/j.jaci.2008.10.050.
 25. Staevska M, Gugutkova M, Lazarova C, Kralimarkova T, Dimitrov V, Zuber‑
bier T, et al. Night‑time sedating H1‑antihistamine increases daytime 
somnolence but not treatment efficacy in chronic spontaneous urticaria: 
a randomized controlled trial. Br J Dermatol. 2014;171:148–54.
 26. Grattan C. Night‑time sedating H1‑antihistamine increases daytime 
somnolence but not treatment efficacy in chronic spontaneous urticaria: 
a randomized controlled trial. Br J Dermatol. 2014;171:8–9.
 27. Summary of product characteristics of desloratadine 5 mg tablets. http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_‑_Product_
Information/human/000313/WC500025540.pdf.
 28. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to 
daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 
2002;22:511–5.
 29. Balp M‑M, Vietri J, Tian H, Isherwood G. The impact of chronic urti‑
caria from the patient’s perspective: a survey in five European coun‑
tries. Patient Patient Cent Outcomes Res. 2015;8:551–8. doi:10.1007/
s40271‑015‑0145‑9.
